ArticleScience advances2025
Proteolytic-resistant self-assembling peptide nanofibers combat specific bacterial infections via trap and kill.
Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Peptide-Enabled Nanoplatforms for Malaria and Leishmaniasis: From Intracellular Targeting to Translational Diagnostic Perspectives.ChemMedChem · 2026Review
- Emerging antimicrobial peptides in gastrointestinal disorders: Dual role in immunity and therapy.World journal of gastrointestinal pharmacology and therapeutics · 2026Review
- Assembly delivery of bioactive matters: Advances, challenges, and prospects.Journal of advanced research · 2026Review
- α-Helical peptides: design strategies and recent advances in biomedical applications.Journal of translational medicine · 2026Review
- The Potential of Non-Ribosomal Peptide Engineering for Creating New Antimicrobial Complexes.Molecules (Basel, Switzerland) · 2026Review
- Self-assembled nanonetworks of highly stable gemini surfactant-like peptides: antibacterial mechanisms, self-assembly characteristics, and in vivo anti-infection potential.Journal of nanobiotechnology · 2026Article
- Emerging Nanomedicine Strategies for Sepsis: Immunomodulation and Beyond.Research (Washington, D.C.) · 2026Article
- Synergistic bactericidal activity of a ginsenoside-copper nano-agent against gram-positive and gram-negative biofilm bacteria.Frontiers in microbiology · 2026Article
- Dietary supplementation with sodium isobutyrate enhances growth performance and colonic barrier function in weaned piglets via microbiota-metabolite-host interactions.Journal of animal science and biotechnology · 2025Article
- Utilizing Proteolytic-Resistant Nano-Short Peptide Based on Naphthyl Tail-Anchored to Combat Bacterial Infections.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Virulence-Selective Trap-Capture-Kill Antibacterial Nanostructures With Immune-Metabolic Regulation for Treating Implant-Associated Infections.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rise in global antibiotic resistance highlights the urgent need for effective antimicrobial agents. Antimicrobial peptides (AMPs) offer a potential solution to combat bacterial resistance. However, key challenges remain in addressing the limitations of current peptide drugs and biomaterials, such as narrow action modes, poor protease stability, and challenges in pathogen-specific targeting. This study introduces a series of multifunctional AMPs by integrating self-assembling systems. By regulating the length of cationic amino acid side chains, the optimized peptide Nhar was identified as a triple-functional candidate with the potential to solve these limitations. In aqueous solutions, Nhar self-assembles into nanofibers that trap pathogens, prevent their spread, and selectively kill Gram-positive bacteria. Nhar demonstrates remarkable protease resistance, retaining antimicrobial activity even under protease conditions (10 milligrams per milliliter). It induces bacterial death primarily through membrane disruption and multiple synergistic mechanisms. In a
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.